drugset / Trial / NCT00280878
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV).
Timeline
- Start
- 2006-01
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Vinorelbine | Small molecule | — | — |